Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase I/II study of SKB264 in unresectable locally advanced or metastatic solid tumors refractory to standard therapy
CTR20201069Phase 2Active
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- Sep 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in Nonhematologic neoplasms, breast cancer, epithelial ovarian cancer (EOC), non-small cell lung cancer (NSCLC), gastric adenocarcinoma, sponsored by Sichuan Kelun-Biotech Biopharmaceutical. Started Sep 2020; status: active.
02
Drugs
sacituzumab tirumotecan
03
Conditions
Nonhematologic neoplasmsbreast cancerepithelial ovarian cancer (EOC)non-small cell lung cancer (NSCLC)gastric adenocarcinoma
Beyond the preview
Go deeper on CTR20201069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201069.